Two-year outcome of Galantamine treatment in Alzheimer’s disease in a routine clinical setting.
Objectives: To describe and evaluate the two-year outcome on cognition (MMSE, ADAS-cog) and global rating (CIBIC) of galantamine treatment in Alzheimer’s disease (AD) in a routine clinical setting. Methods: The Swedish Alzheimer Treatment Study (SATS) is an open, longitudinal, multicenter study evaluating cholinesterase inhibitor (ChEI) treatment in AD. Patients are investigated at baseline, at 2